Entire-body PET Scans for Multiple Sclerosis

Study acronym: EPSMS
StatusRecruiting
PhaseEarly Phase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years 3 months later Sep 30, 2025 → Dec 30, 2027
See other at-risk trials from Brain Health Alliance

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Sep 30, 2025 to Dec 30, 2027 Show 4 more changesShow less
    • Study completion pushed from Dec 30, 2025 to Jun 30, 2028
    • Eligibility criteria expanded, about 9 words
    • Collaborators expanded, about 15 words
    • Publications: details revised at 1 of 1 entry
  2. Primary completion date: Apr 30, 2024 to Sep 30, 2025
    • Start date: Apr 30, 2023 to Sep 30, 2024
    • Study completion date: Oct 30, 2024 to Dec 30, 2025
    • Publications expanded, about 40 words
    v5
  3. Primary completion date: Mar 31, 2023 to Apr 30, 2024
    • Start date: Sep 1, 2022 to Apr 30, 2023
    • Study completion date: Sep 1, 2023 to Oct 30, 2024
    • Eligibility criteria shortened, about 9 words
    v4
  4. Start date changed from estimate of Jun 1, 2022 to Sep 1, 2022
    • Primary completion date: Dec 31, 2022 to Mar 31, 2023
    • Study completion date: Jun 1, 2023 to Sep 1, 2023
    v3
  5. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Dec 1, 2021 to Dec 31, 2022
    • Start date: Mar 1, 2021 to Jun 1, 2022
    • Study completion date: Mar 1, 2022 to Jun 1, 2023
    • Site details revised
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
To evaluate whether an entire-body positron emission tomography (PET) scanner can be exploited to improve evaluation, monitoring and measurement of both peripheral and central demyelination in multiple sclerosis (MS) patients.
Trial Details
NCT Number NCT04390009
Lead Sponsor Brain Health Alliance
Collaborators: Center for Molecular Imaging & Therapy, Shreveport LA, Northern California PET Imaging Center, Sacramento CA
Conditions
(from sponsor)		 Multiple Sclerosis
Related terms Multiple Sclerosis
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov